In patients with hypertriglyceridaemia, icosapent ethyl (IPE) demonstrated significant regression of low attenuation plaque (LAP) volume compared with placebo over 18 months.
Educational partners and supporters
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
Financial support was provided as a GMG Knowledge Gap Grant from Pfizer Inc.
